FOLH1 and neoplasm: Our data demonstrate a change of PSMA-PET expression during systemic therapy of mRCC in the majority of patients; even a complete remission of PSMA-expression was observed in 3/11 patients (27.2%) despite remaining tumor mass with SD on CT (Fig. 2).